Integrated Diagnostics Holdings PLC Notice of Results (7832R)
March 05 2019 - 2:02AM
UK Regulatory
TIDMIDHC
RNS Number : 7832R
Integrated Diagnostics Holdings PLC
05 March 2019
Integrated Diagnostics Holdings Plc
Notice of results
5 March 2019
(London) - Integrated Diagnostics Holdings ("IDH," "the Group,"
or "the Company"), IDHC on the London Stock Exchange, a leading
consumer healthcare company with operations in Egypt, Jordan, Sudan
and Nigeria, will publish its results for the year ended 31
December 2018 on Thursday 21 March 2019 at 7am GMT.
An analyst and investor presentation will be hosted at the
offices of Hudson Sandler, 25 Charterhouse Square, EC1M 6AE at 2pm
GMT on Thursday 21 March 2019. A live audio webcast will be
available on the Group's website at www.idhcorp.com.
Please email idh@hudsonsandler.com if you would like to attend
the presentation.
Contact
IDH +20 (0)2 3345 5530
Sherif El-Ghamrawi, +20 (0)10 0447 8699
Investor Relations Director sherif.elghamrawi@idhcorp.com
Hudson Sandler (International Media
relations) +44 (0) 207 796 4133
Dan de Belder idh@hudsonsandler.com
Bertie Berger
About Integrated Diagnostics Holdings
IDH is a leading consumer healthcare company in the Middle East
and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The
Group's core brands include Al Borg and Al Mokhtabar in Egypt, as
well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in
Sudan) and Echo-Scan (Nigeria). A long track record for quality and
safety has earned the Company a trusted reputation, as well as
internationally recognised accreditations for its portfolio of over
1,400 diagnostics tests. From its base of 405 branches as of 30
June 2018, IDH will continue to add laboratories through a Hub,
Spoke and Spike business model that provides a scalable platform
for efficient expansion. Beyond organic growth, the Group's
expansion plans include acquisitions in new Middle Eastern and
African markets where its model is well-suited to capitalise on
similar healthcare and consumer trends and capture a significant
share of fragmented markets. IDH has been a Jersey-registered
entity with a Standard Listing on the Main Market of the London
Stock Exchange (ticker: IDHC) since May 2015.
IDH's forward-looking strategy rests on leveraging its
established business model to achieve four key strategic goals,
namely: (1) continue to expand customer reach; (2) increase the
number of tests per patient; (3) expand into new geographic markets
through selective, value-accretive acquisitions; and (4) introduce
new medical services by leveraging the Group's network and
reputable brand position. Learn more at idhcorp.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORDMGGFDDMGLZM
(END) Dow Jones Newswires
March 05, 2019 02:02 ET (07:02 GMT)
Integrated Diagnostics (LSE:IDHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Integrated Diagnostics (LSE:IDHC)
Historical Stock Chart
From Apr 2023 to Apr 2024